
Sign up to save your podcasts
Or


Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
By The Uromigos4.9
5757 ratings
Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

21,954 Listeners

32,246 Listeners

30,609 Listeners

504 Listeners

1,309 Listeners

14 Listeners

59 Listeners

8,876 Listeners

23 Listeners

2 Listeners

59 Listeners

2,030 Listeners

2,131 Listeners

195 Listeners

45 Listeners